Developing new antiviral agents using specialized peptides

Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents

NIH-funded research Indiana University Indianapolis · NIH-11243888

This study is exploring new types of molecules that can better target and fight viruses, like the coronavirus, which could lead to improved treatments for patients.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionIndiana University Indianapolis NIH-funded
Lab location1 site (Indianapolis, United States)
Project IDNIH-11243888 on NIH RePORTER

What this research studies

This research focuses on creating bicyclic peptides, which are unique molecules with two interconnected rings that can bind more effectively to viral proteins. By using a technique called phage display, researchers aim to discover these peptides from large libraries, enhancing their ability to target and neutralize viruses like the novel coronavirus. The study involves innovative methods to incorporate specific amino acids into these peptides, potentially leading to more effective antiviral therapies. Patients may benefit from new treatments that are developed through this advanced peptide technology.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals affected by viral infections, particularly those caused by coronaviruses.

Not a fit: Patients with viral infections not related to coronaviruses may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of novel antiviral medications that are more effective against viruses.

How similar studies have performed: Previous research has shown promise in using similar peptide-based approaches for antiviral drug development, indicating potential for success in this area.

Where this research is happening

Indianapolis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.